Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC by Hornung, R et al.
Malignant pelvic tumours (including carcinoma of the colon, the
prostate, the bladder, the cervix, the uterine endometrium and the
ovaries) contribute to 36% of all new cancer cases and 16% of all
cancer related deaths (Parker et al, 1996). Ovarian cancer repre-
sents 5% of cancer deaths in women but is the cause of the greatest
number of gynaecological deaths in the developed world (Boring
et al, 1994). The lack of symptoms in the early stages of ovarian
cancer means that up to 80% of newly diagnosed patients will
have disease that is advanced and often not totally resectable. The
prognosis of these women is poor, with about 20% surviving for 5
years after diagnosis (Pettersson, 1995).
A mainstay of treatment is surgical tumour debulking since
survival is significantly improved if optimal surgical cytoreduc-
tion is achieved prior to chemotherapy (Curtin et al, 1997;
Munkarah et al, 1997). Unfortunately, two-thirds of the patients
with advanced ovarian cancer cannot be optimally debulked
(Schwartz, 1997) because of unresectable, bulky tumours in the
cul-de-sac or upper abdomen, or due to retroperitoneal tumours
adherent to major abdominal vessels (Gershenson, 1994). Electro-
cautery (Deppe et al, 1986), argon beam coagulator (Brand and
Pearlman, 1990), Cavitron Ultrasonic Surgical Aspirator (CUSA)
(Deppe et al, 1990) and neodymium-yttrium-aluminium-garnet
(Nd-YAG) lasers (Brand et al, 1988) are used to improve cyto-
reductive surgery. Most of these techniques require an open
surgical procedure, none are selective for cancerous tissue, and
their beneficial impact on cytoreduction remains unproven
(Gershenson, 1994). Hence, a new tumour debulking technique,
suitable for open surgical procedures in curative intent, or for
minimally-invasive palliative procedures is of the utmost clinical
importance.
The importance of photodynamic therapy (PDT) in the treat-
ment of malignant tumours is currently being evaluated. PDT is
based on the preferential uptake and/or retention of a photosensi-
tizer by malignant tissues (Gomer and Dougherty, 1979; Barr et al,
1990; Chatlani et al, 1992). Irradiation of the tissue containing the
photosensitizer with light of appropriate wavelength and energy
leads to oxidation-mediated tissue necrosis (Weishaupt et al, 1976;
Kimel et al, 1989). Selective tumour destruction can be achieved
in three ways: (1) administering a drug that preferentially localizes
in tumour tissue; (2) applying a drug that distributes similarly in
all tissues but PDT affects the tumour more than normal tissues;
and (3) focusing the light on the tumour only (Moan and Berg,
1992). In ovarian cancer promising attempts to use PDT for
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Summary Interstitial photodynamic therapy (PDT) using the pegylated photosensitizer PEG-m-THPC was evaluated as a minimally-invasive
procedure to selectively debulk unrespectable pelvic ovarian cancer (NuTu-19) in immunocompetent rats. To assess tumour selectivity, PEG-
m-THPC at dosages of 0.3, 3.0 and 30 mg kg–1 body weight was administered intravenously to 30 rats 4 weeks following tumour induction.
Eight days later laser light at 652 nm and optical doses ranging from 100 to 900 J cm–1 diffuser-length was delivered by an interstitial cylindrical
diffusing fibre inserted blindly into the pelvis. Three days following light application, the volume of necrosis was measured and the damage to
pelvic organs was assessed histologically on cross sections. For analysis of survival, 20 tumour-bearing rats received PDT using drug doses
of 3 or 9 mg kg–1 body weight and an optical dose of 900 J cm–1 diffuser-length, whereas ten untreated tumour-bearing rats served as controls.
The histological assessment of PDT induced necrosis showed a non-linear dose–response for both the photosensitizer dose and the optical
dose. The lowest drug dose activated with the highest optical dose did not induce more necrosis than seen in tumour-bearing control animals.
The same optical dose induced necrosis of 17 mm in diameter using 30 mg kg–1 and 11 mm using 3 mg kg–1 photosensitizer. The optical
threshold for induction of significant necrosis was between 100 and 300 J cm–1 diffuser-length for 30 mg kg–1 and between 300 and 500 J cm–1
for 3 mg kg–1 PEG-m-THPC. Significant damage to normal pelvic organs was only seen if 30 mg kg–1 photosensitizer was activated with optical
doses of 700 J cm–1 or more. In the survival study, all treated animals survived PDT for at least 2 weeks and the intestinal and urinary tract
remained functional. No clinical signs of blood vessel or nerve injury were observed. Mean overall survival of untreated tumour-bearing rats
was 25.0 ± 4.5 days compared to 38.4 ± 3.8 days and 40.0 ± 3.6 days for rats treated with 3 mg kg–1 or 9 mg kg–1 PEG-m-THPC mediated PDT
respectively (P < 0.05). We conclude that PEG-m-THPC mediated PDT has a favourable therapeutic window and that this minimally-invasive
procedure can reduce pelvic cancer bulks effectively and selectively. © 1999 Cancer Research Campaign
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Correspondence to: Y Tadirdisseminated small peritoneal metastasis have been proposed
(Tochner et al, 1985, 1986, 1991; Delaney and Glatstein, 1988;
DeLaney et al, 1991, 1993; Sindelar et al, 1991; Goff et al, 1994,
1996; Veenhuizen et al, 1994; Molpus et al, 1996; Lilge et al,
1998). However, the geometric complexity and the large surface
of the human peritoneum make light dosimetry for intraperitoneal
PDT difficult. Furthermore, chemotherapy is an effective treat-
ment modality for diffuse, small residual cancer nodules persisting
after surgical debulking. In contrast, the potential of PDT to
debulk non-resectable pelvic cancer in a minimally-invasive
procedure has not yet been evaluated.
Many photosensitizers have been evaluated for their ability to
preferentially localize in malignant tissue, commonly expressed as
the tumour to tissue ratio (TTR). Porphyrin derivatives are the
most commonly administered photosensitizers. Modifications to
the porphyrin structure (Bonnett and Berenbaum, 1989; Bonnett
et al, 1989) have produced the so-called second-generation
photosensitizers, including the phthalocyanines (Ben-Hur and
Rosenthal, 1985; Rosenthal, 1991) and chlorins (Gomer, 1991)
with TTR values ranging from 1:1 to 5:1 (Pass, 1993). Meso-
tetra(hydroxyphenyl)chlorin (m-THPC) is a chlorin photosensi-
tizer with promising properties. M-THPC has been found to be
extremely effective in animal tumour models, as well as in clinical
trials (Bonnett and Berenbaum, 1989; Ris et al, 1991; 1993a,
1993b; Peng et al, 1995; Wierrani et al, 1997) and it shows selec-
tive uptake by malignant tissues. However, preparation of this
photosensitizer in aqueous solution for systemic application is
difficult due to its hydrophobicity. The addition of four long
hydroxyl (polyethylene glycol, PEG 2000) side-chains linked
to m-THPC through a triazine group produces a tetrakis-
(m-methoxypolyethylene glycol) derivative of 7,8-dihydro-
5,10,15,20-tetrakis(3-hydroxyphenyl)-21-23-[H]-porphyrin
(PEG-m-THPC). PEG-m-THPC is characterized by high
hydrophilicity and lack of instability in vitro (Grahn et al, 1997).
The molecular weight of this water soluble compound is 6515
Daltons compared to 680 Daltons for its hydrophobic parent sensi-
tizer, m-THPC. The relatively large size and the hydrophilicity of
this pegylated compound make it a unique photosensitizer. In a
fluorescence microscopy study (manuscript in preparation) we
demonstrated highly selective targeting of cancer tissue by PEG-
m-THPC in an immunocompetent rat ovarian cancer model.
Tumour fluorescence was maximal 8 days following intravenous
injection of PEG-m-THPC and approximately 40 times higher
than fluorescence of most abdominal organs.
The aim of this study is twofold: first to assess in a histological
study the selectivity of debulking pelvic ovarian cancer masses in
the rat by PEG-m-THPC mediated interstitial PDT. Second to
evaluate the impact of this minimally-invasive treatment on the
survival of rats bearing bulky pelvic ovarian cancers.
MATERIALS AND METHODS
Tumour model
Seventy-two pathogen-free female Fischer 344 rats (Harlan
Sprague Dawley, Inc., IN, USA), weighing 220 g (± 24 s.d.) were
housed in a pathogen-free animal facility and given commercial
basal diet and water ad libitum. The study was approved by
the Institutional Laboratory Animal Care and Use Committee,
University of California, Irvine.
The NuTu-19 cell line is a poorly-differentiated epithelial
ovarian cancer cell line derived from the Fischer 344 rats (Testa
et al, 1994). This syngeneic rat tumour model was chosen because
these cells grow and metastasize in immunocompetent rats in the
same way epithelial ovarian cancers do in humans (Rose et al,
1996).
Cells were cultured in RPMI-1640 medium (Gibco Life
Technologies, Grand Island, NY, USA) enriched with 10% fetal
calf serum (FCS; Gemini Bioproducts, Calabassas, CA, USA),
25 IE ml–1 penicillin and 25 mg ml–1 streptomycin and incubated
under standardized conditions (37°C, 7% carbon dioxide, 100%
humidity). The NuTu-19 cells were harvested with 0.25% trypsin
(Gibco Life Technologies) from tissue culture flasks and washed
with phosphate-buttered saline (PBS; Gibco Life Technologies). A
total of 20 million cells was injected into the caudal part of the
right psoas muscle through a 15 mm lower median laparotomy
which was closed in two layers. Four weeks following tumour
inoculation bulky pelvic tumours measuring 2.5 cm in diameter
developed. Tumour masses protruded out of the osseous pelvis
leading to tumour volumes greater than that of the normal rat
pelvis. All invasive procedures were carried out under isoflurane
(Forane, Ohmeda PPD Inc. Liberty Corner, NJ, USA) -oxygen gas
anaesthesia. Five millilitres lactated Ringer solution (Abott
Laboratories, North Chicago, IL, USA) was given subcutaneously
(s.c.) prior to laparotomy or PDT and 0.5 ml enrofloxacin (Baytril,
Bayer Corp., Shawnee Mission, KA, USA) was injected s.c. prior
to surgery or following PDT. During all procedures, body temper-
ature was kept constant using a heating pad.
PDT
The photosensitizer, PEG-m-THPC, was kindly provided by Scotia
Pharmaceuticals Ltd (Guildford, UK; SC 102, Batch # HR/1/063).
The crystalline photosensitizer was dissolved in distilled water to
concentrations ranging from 25 to 0.25 mg ml–1 (corresponding to
2.6–0.026 mg ml–1 of equimolar concentrations of active m-THPC),
and sterilized by microfiltration through a 0.22-mm filter unit
(Millex-GS, Millipore Corp. Bedford, MA, USA).
Four weeks following tumour induction, 0.3, 3, 9, or 30 mg
PEG-m-THPC-powder per kg body weight was injected into the
tail vein. Eight days following drug application photoactivation
was performed as follows. Through a 2 mm skin incision, a 13-
gauge needle was blindly inserted paramedian right, parallel to the
vertebral column, piercing the anterior abdominal wall, through the
tumour and the entire pelvis until the needle tip arrived underneath
the skin close to the tail. A cylindrical light diffuser (25-mm length,
1.6-mm diameter coupled to a 0.7-mm optical fibre; Optiguide
Fibre Optic DCYL25, QLT PhotoTherapeutics Inc., Seattle, WA,
USA) was placed in the pelvis through the needle. The needle was
then withdrawn, placing the cylindrical light diffuser in direct
contact with the tissues. Laser-light, generated by an argon-pumped
dye laser (Spectra-Physics 171 and Spectra-Physics Model 375,
Mountain View, CA, USA) was launched into the diffusing fibre.
The laser was tuned to 652 nm as verified by a clinical Hartridge
Reversion Spectroscope (Ealing Electro-Optics, South Natick, MA,
USA). The power was measured using an integrating sphere
(Intragold IS 060, LabSphere, North Houston, NH, USA) coupled
to a power meter (model 210, Coherent Corp., Palo Alto, CA,
USA) and kept constant at 150 mW cm–1 diffuser-length which is
below threshold levels for thermal damage (Lowdell et al, 1993).
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(Lowdell et al, 1993). Pelvic tumours were exposed to various
optical doses of laser light (100, 300, 500, 700 or 900 J cm–1
diffuser-length) by varying exposure time from 11 to 100 min.
Histological study
Thirty-nine rats were used for histological assessment of necrosis.
Following drug doses were used: 30, 3 and 0.3 mg kg–1 PEG-m-
THPC. The photosensitizer was activated with either 100, 300,
500, 700 or 900 J cm–1 laser-light in rats sensitized with 30 mg kg–1
PEG-m-THPC. Optical doses of either 300, 500, 700 or 900 J cm–1
were used in rats sensitized with 3.0 mg kg–1 PEG-m-THPC, and
an optical dose of 900 J cm–1 was used to activate 0.3 mg kg–1
PEG-m-THPC. At least three rats were used for every
drug–optical dose combination. Four rats were treated with an
optical dose of 900 J cm–1 and 30 mg kg–1 photosensitizer. Two out
of these four rats died during or immediately after PDT and were
not used for histology. Three tumour-bearing rats were used as
controls and not exposed to PDT.
Three days following PDT, the rats were sacrificed with an
intracardiac injection of Eutha-6 (Western Medical Supply,
Arcadia, CA, USA). In order to study PDT effects on both tumour
and normal pelvic organs the entire lower abdomen, including the
tumour, all pelvic organs, and the abdominal wall without skin was
removed ‘en-bloc’. Following fixation and decalcification (Rapid
Bone Decalcifier RDO, Apex Engineering Products Corporation,
Plaintiel, IL, USA) five transversal, 6- to 8-mm thick sections were
taken from each pelvis, sectioned to 6-mm thick slices, and stained
with haematoxylin and eosin (H&E).
Histology slides were analysed for both the area of PDT-induced
necrosis and for damage to normal tissues. The overall damage
was defined as the volume of necrosis including adjacent
perinecrotic inflammation. The margins of necrosis were marked
with a permanent marker. Histology slides and a ruler were
scanned (Umax Vista-SGE, Umax Data Systems Inc., Hsinchu,
Taiwan; Photoshop, Adobe Systems Inc, Mountain View, CA,
USA) into a computer. The area of PDT induced necrosis was
measured using microscope-calibrated image processing software
(IPlab software, Signal Analytic, Vienna, VA, USA). The average
area of necrosis was calculated from at least three transversal
sections per rat. The volume (cm3) of necrosis was calculated from
the product of the mean necrotic area (cm2) and the length of the
cylindrical light diffuser (cm). To compare the volume of PDT-
induced necrosis to the volume of a normal rat pelvis, the average
volume of the osseous pelvic cavity was calculated in four non-
tumour-bearing rats.
In order to assess selectivity of PDT, damage to normal organs
was determined by a numerical scoring system. Each of the pelvic
organs (i.e. colon, ureters, urinary bladder, vagina, uterus, major
abdominal and pelvic vessels, pelvic muscles and interstitial
connective tissues) were scored as follows: 0 = no damage; 1 =
severe oedema; 2 = necrosis of the muscle or mucosal layer; 3 =
necrosis of the muscle and mucosal layer. Each organ was scored
on five transversal sections. In paired organs the highest score
attributed to a specific organ was multiplied by a factor of two, if
bilateral damage was found, assuming the worst case. In unpaired
organs the highest score attributed was multiplied by a factor of
two, if more than 50% of the organ circumference was damaged in
order to quantify the extent of damage. In addition, scores were
multiplied by a factor of two, if damage to a specific organ was
seen in more than one of the five transversal planes through the
pelvis. The sum of all organ scores per rat was calculated and
divided by the greatest possible damage score to express the rela-
tive damage per rat. Relative damage was expressed with a 0–1
scoring range with 1 indicating all organs were destroyed, and e.g.
0.3 indicating 30% of the greatest possible damage was found.
Survival study
In order to assess the impact of PDT on the functional integrity
of the pelvic organs and on tumour progression, 30 rats were
randomly assigned to either ‘control’ (tumour-bearing but no PDT,
n = 10), or ‘treatment’ groups (3 or 9 mg kg–1 PEG-m-THPC;
optical dose 900 J cm–1 each; n = 10 per group). Animals were kept
alive without special protection from room light, and checked for
weight, eye colour, defecation, urination and behaviour daily (data
not shown). The study end point was defined as spontaneous death
or sacrifice due to following ethical reasons: increase or decrease
of body weight by more than 10% over a period of 3 days in
combination with either anaemic eyes or lack of defecation or
urination for at least 3 days. Based on these clinical symptoms,
severe cancer-related complications such as haemorrhagic ascites
and/or obstruction of the intestinal or urinary pathways or rejection
of food were assumed and sacrifice was indicated.
Data analysis
The volume of necrosis and the score of relative damage to normal
organs were averaged for three rats per given photosensitizer and
optical dose. Data are presented as mean values ± standard error.
For statistical analysis of differences in tumour necrosis at various
PDT for bulky pelvic rat ovarian cancer 633
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Figure 1 The mean volume (cm3) of necrosis ± s.e.m. in the rat pelvis is
displayed as a function of the optical dose of laser light (J cm–1). Data are
shown separately for three different PEG-m-THPC concentrations
(30 mg kg–1, 3 mg kg–1, 0.3 mg kg–1). Spontaneous necrosis of tissues in
tumour-bearing rats which were not exposed to either PEG-m-THPC or laser
light are shown as a circle at the optical dose ‘0 J cm–1’ (controls). ‘X’
represents the mean volume of the normal rat pelvis (at 0 J cm–1). n = 3 rats
per given optical dose (exception: at 900 J cm–1 and 30 mg kg–1 n = 2)optical doses or damage scores at various optical doses the
Kruskal–Wallis test was used. If a significant overall difference
was present, multiple comparisons were performed using the
Bonferroni–Dunn multiple comparison procedure. Cumulative
survival was calculated using the Kaplan–Meier survival analysis
(Kaplan and Meier, 1958). Statistical significance for survival
analysis was calculated using the Peto-Peto–Wilcoxon test. P-
values < 0.05 were considered significant for all statistics.
RESULTS
Volumes of PDT-induced necrosis are shown in Figure 1 as a func-
tion of optical dose (J cm–1) for the three drug concentrations (30,
3 and 0.3 mg kg–1 PEG-m-THPC) used in the histological study.
Spontaneous necrosis in tumour bearing rats exposed to neither
drug nor light measured 0.4 ± 0.5 cm3 and is referred to as the
optical dose ‘0 J cm–1’. The mean volume of four normal rat
pelvises was 2.4 ± 0.14 cm3 and is shown at the position ‘0 J cm–1’.
The lowest drug dose (0.3 mg kg–1 PEG-m-THPC) activated with
the highest optical dose (900 J cm–1) did not induce more necrosis
than found in tumour-bearing control animals. We conclude that
0.3 mg kg–1 PEG-m-THPC does not induce photosensitization and
900 J cm–1 laser light does not induce relevant thermal damage. A
tenfold higher photosensitizer concentration (3 mg kg–1 PEG-m-
THPC) activated with the same optical dose (900 J cm–1) induced
an overall damage close to the volume of the treated pelvises.
Using the highest drug concentration (30 mg kg–1 PEG-m-THPC)
and the highest optical dose (900 J cm–1), the volume of necrosis
doubled that of a normal pelvis. The volume of necrosis can
exceed that of the anatomical pelvis since the tumour-bulk
protrudes out of the osseous pelvis. Differences between volumes
of necrosis induced with the three dosages of PEG-m-THPC were
statistically significant (P < 0.05) at any given optical dose. For
the highest optical dose used, the depth of necrosis measured from
the surface of the light diffuser was 8.5 mm with 30 mg kg–1, and
5.5 mm with 3 mg kg–1. The optical threshold for induction of
significant necrosis was between 100 and 300 J cm–1 diffuse length
for the highest drug concentration, and between 300 and 500 J
cm–1 for 3 mg kg–1 PEG-m-THPC. Increasing the optical dose
resulted in a non linear dose–response. An optical dose
above 700 J cm–1 diffusing-fibre did not substantially increase the
volume of necrosis.
The impact of PEG-m-THPC mediated PDT on normal pelvic
organs is displayed in Figure 2 as a function of the optical dose
for the three drug concentrations used. Spontaneous damage to
organs, such as tissue destruction by tumour infiltration, is shown
634 R Hornung et al
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Figure 2 The impact of PEG-m-THPC sensitized minimally-invasive PDT
on normal pelvic organs (i.e. colon, ureters, urinary bladder, vagina, uterus,
major abdominal and pelvic blood vessels, pelvic muscles, and interstitial
connective tissue) was assessed on cross sections through the pelvises of
tumour-bearing rats. The relative damage to normal pelvic organs (score of
the examined rat divided by the greatest possible damage score) is shown as
a function of the optical dose (J cm–1). Scores for various concentrations (30,
3, 0.3 mg kg–1) of the photosensitizer PEG-m-THPC are shown. Spontaneous
damage to organs, such as tissue destruction by tumour infiltration, are
shown at the position ‘0 J cm–1’ (controls). n = 3 rats per given optical dose
(exception: at 900 J cm–1 and 30 mg kg–1 n = 2)
Figure 3 Two representative H&E-stained micrographs (10´ magnification)
of cross sections through the lower abdomen of a rat sacrificed 3 days after
minimally-invasive PDT of a bulky pelvic tumour are shown. The animal was
treated with 700 J cm–1 fibre-length of laser-light at 652 nm 8 days following
intravenous injection of 30 mg kg–1 PEG-m-THPC. Both micrographs show
completely necrotic tumour masses (1) encompassing normal pelvic organs
such as the colon (2), the ureter (3), and the urinary bladder (4). A strong
inflammatory reaction is infiltrating the necrosis (5). Although the light-diffuser
was in immediate vicinity of the pelvic organs, they show intact epithelial
layers (6) with moderate oedema of the underlying connective tissues (7).
The muscle layers (8) of the colon and the ureter are histologically intact and
neither megacolon nor hydroureter can be seen, suggesting that the smooth
muscles remained functional. The muscle layers of the urinary bladder are
partially intact and partially destroyed (9) which may be due to either adverse
effects of PDT or to successfully treated tumour masses that previously
infiltrated and destroyed the wall of the urinary bladder. (Bars indicate
0.25 mm)at the position ‘0 J cm–1’ (controls). PDT using the lowest
(0.3 mg kg–1) or the middle (3 mg kg–1) drug doses did not induce
more damage to normal organs than found in control animals. In
contrast, the highest photosensitizer dose (30 mg kg–1) induced
more damage to normal tissues compared to controls when optical
doses of 700 J cm–1 or more were used. These data suggest that a
therapeutic window for PEG-m-THPC mediated PDT does exist
where tumour necrosis occurs (Figure 1) and normal tissues are
spared (Figure 2).
Figure 3 shows two representative H&E stained micrographs
(10´ magnification) of cross-sections through the lower abdomen
of a rat sacrificed 3 days following PDT. The optical dose was
700 J cm–1 fibre-length and the drug dose was 30 mg kg–1 PEG-
m-THPC. Both micrographs show completely necrotic tumour
masses (1) encompassing normal pelvic organs such as the colon
(2), the ureter (3) and the urinary bladder (4). Necrosis is
surrounded by a strong inflammatory reaction (5). Although the
light-diffuser was in the immediate vicinity of the pelvic organs,
they show intact epithelial layers (6) with oedema of the under-
lying connective tissue (7). Musculature (8) of colon and ureter is
histologically intact. The muscle layers of the urinary bladder (9)
are partially destroyed. This may be due to an adverse effect of
PDT on healthy tissue or due to successfully treated tumour
masses that previously infiltrated and destroyed the wall of the
urinary bladder.
Interestingly, hollow organs such as ureters, major blood vessels
and colon remained patent even when severely damaged. No
sequel of perforation such as uroperitoneum, peritonitis or
haematoperitoneum were seen at necropsy. Increasing the optical
dose from 700 J cm–1 to 900 J cm–1 did not significantly increase
the volume of necrosis, but recovery of rats sensitized with
30 mg kg–1 PEG-m-THPC was substantially slower when treated
with 900 J cm–1 than with 700 J cm–1. Two out of four rats treated
with the highest optical and drug dose did not survive the procedure.
At necropsy no major internal haemorrhage was found in these
animals, suggesting that the pronounced oedema observed induced
severe fluid and electrolyte shifts leading to death. Following PDT,
many rats were limping with the right hind-limb. The degree of
limping appeared to be proportional to the drug–light dose product,
and symptoms disappeared within three days. Hence, we assume
that the limping was induced by swelling of the muscle and the
connective tissue rather than by neural damage or myolysis. Most
rats experienced slight to moderate bleeding from the branch canal
when the light diffuser was withdrawn after completed irradiation.
Bleeding was fatal in four of 55 rats.
The cumulative survival of untreated and treated tumour-
bearing rats is shown in Figure 4 as a function of time (days).
Mean overall survival for untreated tumour-bearing rats was
25.0  ± 4.5 days, whereas mean overall survival of treated rats was
38.4  ± 3.8 days and 40.0 ± 3.6 days for tumour-bearing rats
exposed to 3 or 9 mg kg–1 PEG-m-THPC-mediated minimally-
invasive PDT respectively. Prolongation of survival with PDT was
significant (P < 0.05) for both treated groups compared to controls.
However, PDT using 9 mg kg–1 PEG-m-THPC did not signifi-
cantly prolong survival compared to the group treated with 3 mg
kg–1. All rats treated with PDT survived for at least 2 weeks,
suggesting a lack of toxicity. Neither limb gangrene nor permanent
limb paralysis were observed. All rats exposed to PDT excreted
regularly. Macro-haematuria or blood containing faeces were not
found. These observations indicate that despite the high likelihood
for exposure to laser-light, blood-vessels, nerves, colon, ureters
and urinary bladder remained functional. The skin at the fibre-
insertion-site and next to the anus (i.e. where the fibre emerged)
was always directly exposed to laser light. Surprisingly, none of
the animals showed necrosis in either area, suggesting a lack of
skin photosensitization 8 days after drug administration. Delayed
wound healing at the fibre-insertion-site was not observed.
DISCUSSION
PDT has many theoretical advantages compared to conventional
treatment modalities for cancer: PDT can be repeated without
increased toxicity, it kills cancer cells by a distinct photochemical
mechanism, and the risk of generating secondary cancer is small
since the extent of DNA damage seems to be limited (Moan and
Berg, 1992). Most important is the potential to destroy malignan-
cies selectively if the photosensitizer is retained and/or accumu-
lated preferentially in malignant tissue.
The poor prognosis of advanced ovarian cancer and recent
developments in photomedicine have generated a considerable
interest in PDT for this disease. Tochner et al (Tochner et al, 1985,
1986) have successfully treated small ovarian cancer deposits on
the peritoneal surface with laser-light activated haematoporphyrin
derivative (HpD) in mice. Similarly, intraperitoneal benzopor-
phyrin derivative mono-acid ring A (BPD-MA)-mediated PDT has
been used to treat epithelial ovarian carcinomatosis in a mouse
model, resulting in prolongation of survival (Molpus et al, 1996).
Clinical phase I studies demonstrated promising results in patients
treated with dihaematoporphyrin ethers (DHE) during open
surgery for refractory or recurrent, disseminated intraperitoneal
tumours (Sindelar et al, 1991; DeLaney et al, 1993). A recent study
PDT for bulky pelvic rat ovarian cancer 635
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Figure 4 The cumulative survival (Kaplan–Meier survival analysis) of
untreated tumour-bearing rats and tumour-bearing rats treated with PDT is
shown as a function of time (days). The follow-up of the rats started four
weeks following tumour induction, when bulky tumours had developed. Thirty
rats were randomly assigned (day 0) to either a control group (n = 10), or
groups injected with either 3 mg kg–1 (n = 10), or 9 mg kg–1 PEG-m-THPC
(n = 10). An optical dose of 900 J cm–1 of laser light in both PDT groups was
applied blindly to the pelvis in a minimally-invasive procedure (day 8). Rats
treated with PDT showed a significant prolongation of survival (P < 0.05 for
both treated groups). PDT with 9 mg kg–1 PEG-m-THPC showed a non-
significant tendency to be more efficient than PDT with 3 mg kg–1 PEG-m-
THPC
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Days of follow uppresented encouraging preliminary data on patients with peritoneal
carcinomatosis due to recurrent ovarian cancer treated with laparo-
scopically guided PDT using m-THPC (Wierrani et al, 1997). All
of these studies focused on eliminating small volumes of diffuse
residual disease. In contrast, the present study assessed the effect
of PDT on non-resectable large volume ovarian cancer bulks in the
pelvis. Earlier studies reported significant morbidity after intra-
abdominal PDT, including perforation in the gastrointestinal tract
and necrotizing pancreatitis. These adverse effects were attributed
to inadequate photosensitizer selectivity and/or light overdose
(Lilge et al, 1998). Unusual high tumour selectivity of the photo-
sensitizer PEG-m-THPC has been shown in a previous fluores-
cence microscopy study in the same tumour model (manuscript in
preparation) eight days following systemic application. In the
present study we showed selective tumour destruction using
moderate drug concentrations which resulted in prolongation of
survival, suggesting selective tumour targeting of PEG-m-THPC.
Only the extremely high drug concentration of 30 mg kg–1 acti-
vated by an optical dose of 700 J cm–1 or more induced significant
damage to normal organs, as demonstrated in the histological
study (Figure 2). Hence, PDT with this photosensitizer seems to
have a broad therapeutical window. To induce tumour necrosis a
minimal drug dose of 3 mg kg–1 body weight and a minimal optical
dose of 300 J cm–1 diffusing fibre was required.
Interstitial PDT was performed by placing the light diffusers
blindly into the pelvis. If a non-selective photosensitization would
have occurred, severe damage to normal tissues would be
expected, with poor survival. It is important to note that normal
organs in treated animals were exposed to significant optical doses
of laser-light as indicated by necrotic tumour masses encom-
passing these organs. In fact, using moderate drug doses damage
to normal tissues in treated rats was equal to controls. Further
evidence for tumour selectivity of PDT is provided by the survival
study (Figure 4). All treated animals survived for at least 2 weeks,
and excreted regularly during that time, indicating functional
integrity of the pelvic organs. Minimally-invasive PEG-m-THPC
mediated PDT of rats bearing pelvic cancer resulted in significant
prolongation of survival compared to tumour-bearing controls.
Our findings are in good agreement with those reported by other
groups. Ris et al (1998) demonstrated that PEG-m-THPC
mediated PDT did not alter normal minipig bronchi, unlike the
equimolar dose of the parent compound which induced ulceration
and necrosis of bronchial mucosa. Westermann et al (1998) found
a tumour to skeletal-muscle ratio of almost 20 for radioactive-
labelled PEG-m-THPC whereas the radioactive-labelled parent
compound reached only a ratio of 6. All of these researchers inves-
tigated drug-light-intervals up to 4 days. Our data strongly suggest
that prolongation of the drug–light interval to 8 days may further
enhance tumour selectivity while the strong PDT effect persists.
This observation can be explained in part by the twofold longer
half-life of PEG-m-THPC in the blood circulation compared to
free m-THPC as described by Westermann et al (1998). Similarly,
pegylation of liposomes seems to extend their longevity in
circulation whereas their uptake by tumours is still possible
due to increased microvascular permeability (Gabizon and
Papahadjopoulos, 1988). For liposomes carrying drugs such as
doxorubicin, it has been shown that pegylation increases selective
accumulation in tumours and enhances anti-tumour activity
(Gabizon et al, 1994).
Vascular shutdown is frequently seen with various photosensi-
tizers. Neither our histology study nor the follow-up of treated rats
in the survival study gave evidence for vascular shutdown. We
consider this as a potentially important observation. Intact blood
and oxygen supply enhances efficacy of subsequent chemotherapy,
radiotherapy, or repeated PDT (Wouters and Brown, 1997). PDT
using PEG-m-THPC may therefore allow combination with estab-
lished treatment modalities.
For translation of this therapeutic concept into clinical use
several adaptations are required. To debulk large tumour volumes,
several fibres with diffusing tips of varying lengths could be
inserted. The placement of laser fibres could be performed under
guidance of an imaging system such as ultrasound, computerized
tomography scan, or magnetic resonance imaging. Variation of
irradiation parameters could further optimize dosimetry in
complex tumour geometry. We did not observe skin lesions at the
fibre insertion site following PDT, suggesting low skin photosensi-
tization. However, there is currently no data on skin photosensiti-
zation of PEG-m-THPC available. Thus, sensitized patients need
to be protected from intense light.
We conclude that minimally-invasive PEG-m-THPC-mediated
PDT has a favourable therapeutic window and can reduce pelvic
cancer bulks effectively and selectively. This approach deserves
further investigation as treatment of non-resectable cancer. The
method may be suitable for tumour debulking during open surgery
or as a minimally-invasive procedure and may be combined with
subsequent chemo- or radiotherapy.
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